COLLABORATION WILL FOCUS ON COLLECTION, PROCESSING AND STORAGE OF EQUINE
CORD BLOOD, BONE MARROW AND PLACENTAL TISSUE STEM CELLS
RANCHO CORDOVA, Calif., Feb. 27 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, announced today that its wholly-owned subsidiary, Vantus, Inc., has signed a formal agreement with the UC Davis School of Veterinary Medicine's Center for Equine Health and its Stem Cell Regenerative Medicine Group. Under the agreement, the two organizations will conduct joint research and development of methods to enhance the collecting, processing and storing of stem cells from equine cord blood, bone marrow and placental tissue. These cells will be used in the development of therapeutics for the prevention and treatment of orthopedic injuries, such as tendon and ligament injuries, in performance horses.
Earlier this month, ThermoGenesis announced the creation of Vantus, a laboratory service company focused on the performance equine market, including Thoroughbreds, American Quarter Horses, Arabians and Warm Bloods. Under this collaboration, the ThermoGenesis MarrowXpress(TM) System and BioArchive(R) System will be used for processing and storage of the stem cells. The Company is currently refining collection methodologies at breeder farms in California and processing methods at UC Davis. Vantus expects to be in operation at the beginning of the foaling season in January of next year.
"As we have indicated, launching Vantus represents a major milestone in
our regenerative medicine diversification strategy. By partnering with UC
Davis, we are joining forces with a recognized world leader in vete
|SOURCE ThermoGenesis Corp.|
Copyright©2008 PR Newswire.
All rights reserved